Neuren Reports 8% Revenue Growth and 68% Profit Decline in H1 2026

Royalty Growth Masks Profit Pressure

Neuren Pharmaceuticals (ASX:NEU) reported a solid 8% increase in revenues to A$42.7 million for the half-year ended 30 June 2026, largely fueled by rising royalties from Acadia Pharmaceuticals’ DAYBUE (trofinetide). The US$23.3 million (A$33.2 million) royalty income marked a 29% increase in US dollars and 17% in Australian dollars, reflecting continued US sales growth and expanded named patient programs internationally.

Yet beneath the top-line growth, net profit after tax plunged 68% to A$4.9 million, down from A$15.0 million in the prior corresponding period. The sharp decline was driven by a substantial A$12.5 million jump in research and development expenses, primarily due to the ongoing Phase 3 Koala trial for NNZ-2591 in Phelan-McDermid syndrome (PMS). Corporate costs rose modestly to A$3.0 million but were offset by A$5.6 million in interest income.

Dividend Policy Signals Confidence

In a notable shift, Neuren introduced its first-ever dividend policy, declaring a fully franked interim dividend of 15.0 cents per share, payable in early October 2026. The dividend is anchored to the growing and recurring royalty income from DAYBUE, marking a milestone in the company’s capital management strategy. This move follows recent on-market share buy-backs totalling A$3.9 million during the half-year, reflecting a balanced approach to returning value to shareholders while funding ongoing development.

Regulatory and Clinical Advances Drive Outlook

DAYBUE’s momentum extends beyond the US, with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopting a positive opinion in June 2026. This was swiftly followed by European Commission marketing authorisation covering the EU plus Iceland, Liechtenstein, and Norway, setting the stage for a commercial launch in Germany in early Q4 2026. This regulatory milestone triggers a US$35 million milestone payment to Neuren, with further potential sales milestones up to US$170 million and tiered royalties ranging from mid-teens to low twenties percent of net EU sales.

Meanwhile, the Japanese trofinetide clinical trial is expected to deliver topline data between September and November 2026, with a regulatory submission planned for 2027 under Orphan Drug designation. This could unlock an additional US$15 million milestone payment and up to US$110 million in sales milestones, along with tiered royalties.

Phase 3 Koala Trial Accelerates Enrolment

Neuren’s NNZ-2591 (ercanetide) continues its clinical push with the Koala Phase 3 trial in PMS, now operating 15 activated sites across the US and Canada, up from just two at the start of 2026. Over 100 potential participants have been referred or are awaiting site activation, with an open-label extension study underway. This trial represents the first Phase 3 study ever conducted in PMS, a rare neurodevelopmental disorder with a higher prevalence than previously estimated, underscoring the unmet medical need.

The company is also preparing for a late October 2026 FDA meeting to discuss trial design for NNZ-2591 in Pitt Hopkins syndrome, a rarer and more severe condition. Neuren is seeking regulatory agreement on an alternative trial approach given the challenges of replicating the PMS study design in this smaller patient population.

Financial Position and Outlook

Neuren ended the period with a strong cash and short-term investment balance of A$286.5 million, slightly down from A$296.1 million at the end of 2025. Operating cash flow slowed to A$8.0 million, reflecting the absence of milestone payments received in the prior year and increased R&D spend. The company remains well capitalised to fund ongoing clinical programs and commercial expansion.

While the profit dip may temper near-term earnings expectations, the combination of accelerating royalty income, regulatory approvals in major markets, and the initiation of dividend payments marks a significant evolution in Neuren’s maturity as a commercial-stage biopharma. The market will be watching the upcoming Japan trial readout, FDA discussions on trial design, and the commercial rollout in Europe closely.